Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa

Detalles Bibliográficos
Autores principales: Iannone, Michela, Janowska, Agata, Tonini, Giulia, Davini, Giulia, Dini, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
COVID-19: Important Updates and Developments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131181/
https://www.ncbi.nlm.nih.gov/pubmed/34809775
http://dx.doi.org/10.1016/j.clindermatol.2021.05.026
_version_ 1783694665087713280
author Iannone, Michela
Janowska, Agata
Tonini, Giulia
Davini, Giulia
Dini, Valentina
author_facet Iannone, Michela
Janowska, Agata
Tonini, Giulia
Davini, Giulia
Dini, Valentina
author_sort Iannone, Michela
collection PubMed
description
format Online
Article
Text
id pubmed-8131181
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-81311812021-05-19 Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa Iannone, Michela Janowska, Agata Tonini, Giulia Davini, Giulia Dini, Valentina Clin Dermatol COVID-19: Important Updates and Developments Elsevier Inc. 2021 2021-05-19 /pmc/articles/PMC8131181/ /pubmed/34809775 http://dx.doi.org/10.1016/j.clindermatol.2021.05.026 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle COVID-19: Important Updates and Developments
Iannone, Michela
Janowska, Agata
Tonini, Giulia
Davini, Giulia
Dini, Valentina
Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
title Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
title_full Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
title_fullStr Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
title_full_unstemmed Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
title_short Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
title_sort safety and efficacy of the bnt162b2 mrna covid-19 vaccine during ixekizumab treatment for hidradenitis suppurativa
topic COVID-19: Important Updates and Developments
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131181/
https://www.ncbi.nlm.nih.gov/pubmed/34809775
http://dx.doi.org/10.1016/j.clindermatol.2021.05.026
work_keys_str_mv AT iannonemichela safetyandefficacyofthebnt162b2mrnacovid19vaccineduringixekizumabtreatmentforhidradenitissuppurativa
AT janowskaagata safetyandefficacyofthebnt162b2mrnacovid19vaccineduringixekizumabtreatmentforhidradenitissuppurativa
AT toninigiulia safetyandefficacyofthebnt162b2mrnacovid19vaccineduringixekizumabtreatmentforhidradenitissuppurativa
AT davinigiulia safetyandefficacyofthebnt162b2mrnacovid19vaccineduringixekizumabtreatmentforhidradenitissuppurativa
AT dinivalentina safetyandefficacyofthebnt162b2mrnacovid19vaccineduringixekizumabtreatmentforhidradenitissuppurativa

Ejemplares similares